Alcon to Launch Clareon IOL at ESCRS Meeting

October 6, 2017: By Joan McKenna

alcon-large-3x2Alcon will introduce its new Clareon intraocular lens (IOL) at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, set for Oct. 7-11 in Lisbon, Portugal.

The company describes the Clareon as having the most advanced optic IOL material available. The lens is offered in an automated, disposable, preloaded delivery system.

Alcon, the Texas-based eye care division of Novartis, says it will provide an extensive scientific and educational program at the meeting, with 18 accepted abstracts and more than 10 satellite events.

“We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, chief executive officer of Alcon. “This is a great year for Alcon as we celebrate many important milestones.”

Among those is the 100 millionth implantation of Alcon’s flagship AcrySof lens, Ball said.

Presentations also will include new efficacy and safety data for Alcon’s CyPass Micro-Stent in patients with glaucoma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility